	Program Overview Novel agents and new treatment strategies have driven significant changes in the management of rheumatoid arthritis (RA) over the past 20 years. These agents—including some recently approved, and others emerging from clinical trials—provide therapeutic options after a patient fails standardized therapy. The result has been a dramatic shift in the treatment paradigm for patients with RA. Treatment goals now include the prevention of structural damage and functional decline, and remission rather than mere symptom control. In the absence of recently updated guidelines, improving care for patients with RA can be challenging. These educational activities have been designed to help clinicians integrate the most current RA therapies into clinical practice, optimize treatment, and reevaluate regimens when the disease progresses. Target Audience Rheumatologists and other physicians treating rheumatoid arthritis. Click on the name of a faculty member to view full bio and click once more to close bio.
	Activity Chair Mark C. Genovese, MD Associate Professor of Medicine Co-Chief, Division of Immunology and Rheumatology Stanford University Stanford, California
	Distinguished Faculty Marc D. Cohen, MD Professor of Medicine Chief, Rheumatology National Jewish Medical and Research Center Denver, Colorado
	Paul Emery, MA, MD, FRCP arc Professor of Rheumatology Academic Section of Musculoskeletal Disease University of Leeds, Leeds Teaching Hospitals Trust Leeds Institute of Musculoskeletal Disease Rheumatoid Disease Leeds, United Kingdom
	Eric Ruderman, MD Associate Professor of Medicine Division of Rheumatology Northwestern University, Feinberg School of Medicine Chicago, Illinois
	Sponsorship and Support Statement These activities are sponsored by Veritas Institute for Medical Education, Inc., and supported by an educational grant from Genentech and Biogen Idec. Learning Objectives Based on clinical data, you will be able to critically evaluate the safety and efficacy of anti-tumor necrosis factor (TNF) agents for the management of rheumatoid arthritis (RA). You will be able to evaluate the risks and benefits of maintaining anti-TNF therapy or switching to another regimen for the treatment of a nonresponsive patient with RA. You will be able to use indicators of disease progression to select the most appropriate biological therapies for patients who are intolerant or unresponsive to standard therapy in order to improve patient outcomes. You will be able to evaluate the late-stage clinical data about novel therapies for RA treatment. Method of Participation For the Webinar: View the entire slide presentation and answer all clinical statements and questions embedded in each module of the Webinar. You must complete all three modules to receive the maximum of 2.0 AMA PRA Category 1 Credits^TM. Note: Flash Media Player is required to view this activity. If you do not have Flash Media Player, click here to download. For the Monograph: View or download the Monograph content and answer all clinical statements and questions. For each activity: Complete and submit the CME Activity Evaluation and Request for Credit Form. Print your certificate of credit. These activities are provided free of charge. Accreditation/Designation of Credit Statements Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits.™ Please Note: Each activity is designated for 2.0 AMA PRA Category 1 Credits.™ Financial Disclosure In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Disclosures are as follows: Mark C. Genovese, MD: Abbott Laboratories (speakers bureau, consultant), Bristol-Myers Squibb (speakers bureau, consultant), Genentech (speakers bureau, consultant), Merck Serono (consultant), Pfizer Inc (consultant), Roche Pharmaceuticals (consultant), Wyeth Pharmaceuticals (consultant). Paul Emery, MA, MD, FRCP: Bristol-Myers Squibb (speakers bureau, advisory board), Roche Pharmaceuticals (speakers bureau, advisory board). Eric Ruderman, MD: Abbott Laboratories (consultant), Amgen Inc (consultant), Bristol-Myers Squibb (consultant), Genentech (consultant). Marc D. Cohen, MD: Abbott Laboratories (consultant), Amgen Inc (consultant), Genentech (speakers bureau, consultant), Gentocore (consultant), Wyeth Pharmaceuticals (consultant). The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose. The independent content reviewer for these activities has nothing to disclose. Off-Label/Investigational Uses of Drugs/Medical Devices Disclosure Participants are advised that these CME activities will contain references to unlabeled/ unapproved/investigational uses of drugs to treat patients with rheumatoid arthritis (RA). Disclaimer The opinions expressed in these activities are those of the presenters and do not necessarily reflect those of Veritas Institute for Medical Education, Inc., or Genentech and Biogen Idec. Copyright © 2008 Veritas Institute for Medical Education, Inc. All rights reserved. Privacy Policy & Terms and Conditions